A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity

• Published in: British journal of clinical pharmacology Vol. 75; no. 6; pp. 1433 - 1444
• Main Authors: Jakubowski, Joseph A., Zhou, Chunmei, Small, David S., Winters, Kenneth J., Lachno, D. Richard, Frelinger, Andrew L., Howard, Jo, Mant, Timothy G., Jurcevic, Stipo, Payne, Christopher D.
• Format: Journal Article
• Language: English
• Published: England Blackwell Science Inc 01.06.2013
• Subjects: adenosine diphosphate; Adult; Anemia, Sickle Cell - drug therapy; Anemia, Sickle Cell - metabolism; Blood Platelets - drug effects; Clinical Trials; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Male; P2Y12 receptor antagonist; Piperazines - adverse effects; Piperazines - pharmacokinetics; Piperazines - pharmacology; platelet; Platelet Function Tests; prasugrel; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists - adverse effects; Purinergic P2 Receptor Antagonists - pharmacokinetics; Purinergic P2 Receptor Antagonists - pharmacology; sickle cell; Thiophenes - adverse effects; Thiophenes - pharmacokinetics; Thiophenes - pharmacology; Young Adult

Aims Prasugrel is a novel thienopyridine P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits ADP‐mediated platelet activation and aggregation. Accordingly, it may be useful in reducing platelet‐related ischaemia in sickle cell disease (SCD). Exposure to prasugrel's active metabo...